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ABSTRACT
Despite advances in glioblastoma (GBM) therapy, prognosis of the disease 
remains poor with a low survival rate. Cannabidiol (CBD) can induce cell death and 
enhance radiosensitivity of GBM but not normal astrocytes. Inhibition of ATM kinase 
is an alternative mechanism for radiosensitization of cancer cells. In this study, we 
increased the cytotoxic effects of the combination of CBD and γ-irradiation in GBM 
cells through additional inhibition of ATM kinase with KU60019, a small molecule 
inhibitor of ATM kinase. We observed in GBM cells treated by CBD, γ-irradiation and 
KU60019 high levels of apoptosis together with strong upregulation of the percentage 
of G2/M-arrested cells, blockade of cell proliferation and a massive production of 
pro-inflammatory cytokines. Overall, these changes caused both apoptotic and non-
apoptotic inflammation-linked cell death. Furthermore, via JNK-AP1 activation in 
concert with active NF-κB, CBD upregulated gene and protein expression of DR5/
TRAIL-R2 and sensitize GBM cells to TRAIL-induced apoptosis. In contrast, CBD 
notably decreased in GBM surface levels of PD-L1, a critical immune checkpoint agent 
for T-lymphocytes. We also used in the present study TS543 human proneural glioma 
cells that were grown as spheroid culture. TS543 neurospheres exhibited dramatic 
sensitivity to CBD-mediated killing that was additionally increased in combination 
with γ-irradiation and KU60019. In conclusion, treatment of human GBM by the triple 
combination (CBD, γ-irradiation and KU60019) could significantly increase cell death 
levels in vitro and potentially improve the therapeutic ratio of GBM.
INTRODUCTION
Human gliomas are the most prevalent primary 
tumors of the central nervous system (16% of all 
primary brain tumors). Approximately 54% of all newly 
diagnosed gliomas are glioblastoma (GBM), the most 
malignant and lethal primary brain cancer in adults. 
Despite advances in GBM therapy, outcomes remain 
poor with a median survival rate of 12-15 months after 
initial diagnosis [1, 2]. The standard of care for GBMs 
includes maximal safe surgical resection followed by 
external beam radiotherapy (with a total dose of 60 
Gy) and concurrent temozolomide (as a supplemental 
DNA-damage agent), followed by 6 to 12 months of 
adjuvant treatment with temozolomide [3]. However, 
the vast majority of GBMs eventually relapse and new 
treatment modalities are desperately needed. Normal 
glial cells exhibit a substantial degree of radioresistance, 
while adult neurons, endothelial cells, oligodendrocyte 
precursor cells (OPC) and neural stem/ progenitor cells 
(NSC/NPC), are highly sensitive to ionizing radiation 
alone or in combination with chemotherapy. Clinical 
observations and animal experiments demonstrate that 
cranial irradiation causes substantial cognitive deficits 
due to neuronal and endothelial cell damage, as well as 
inhibition of the proliferation and death of OPC and NSC/
NPC [4–11]. Thus, advances in GBM treatment must not 
only be efficacious but significantly safer.
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At the beginning of this century, killing GBM by 
cannabinoids in vitro and in animal experiments was 
elucidated in numerous studies [12–15]. Additional 
investigations also confirmed the cytotoxic role of 
cannabinoids for several other types of cancer [16–18]. 
A number of studies with GBM cells demonstrated the 
efficiency of combined treatments of cannabinoids 
together with γ-irradiation both in cell culture and 
in animal experiments [19–21]. The advantage 
of substituting a single modality treatment with a 
combination of treatments is the possibility to minimize 
toxicity and to optimize doses of ionizing radiation. On 
the other hand, drugs in combination with radiotherapy 
are often used at a lower dose than in monotherapy. 
Combined therapy may allow attacking several signaling 
pathways in GBMs and potentially overcomes a 
characteristic feature of GBMs to develop treatment 
resistance. Several former studies demonstrated a leading 
role for ATM kinase in regulation of radioresistance of 
cancer cells [22–26]. Specific pharmacological inhibitors 
of ATM kinase activity are currently under preclinical 
and clinical investigation for cancer treatment, including 
upregulation of radiosensitivity of tumors [25]. Based on 
previous studies of the regulation of cell death signaling 
in GBM after combined treatment with cannabidiol 
(CBD) and γ-irradiation [19, 21], we evaluated in the 
present study the impact of a small molecule inhibitor 
of ATM kinase KU60019 [26] as the third component 
of combined treatment to increase the efficacy of GBM 
killing.
RESULTS
Signaling pathways induced by combined 
treatments with CBD, the ATM kinase inhibitor 
KU600199 and γ-irradiation in U87MG human 
GBM cells
ATM kinase plays a crucial role as a sensor 
of double-strand breaks in genomic DNA and as the 
initiator of DNA repair after nuclear ionizing irradiation. 
Furthermore, active ATM kinase affects numerous 
cytoplasmic targets that regulate cell signaling pathways 
and general cell survival [24]. Since ATM kinase 
activation upon γ-irradiation regulates a balance between 
cell survival and death pathways, we used the ATM 
kinase inhibitor KU60019 [26] to investigate its effects 
in combination with CBD on radiosensitization of cancer 
cells. As expected, our initial experiments demonstrated 
efficient phosphorylation of histone H2AX after 
γ-irradiation of U87MG GBM cells, while CBD (20 μM) 
pretreatment did not notably affect basal levels, as well as 
radiation-induced ATM-mediated γ-H2AX foci formation 
(Figure 1A). On the other hand, we observed substantial 
suppression of γ-H2AX foci formation after γ-irradiation 
in the presence of the ATM kinase inhibitor (ATMi) 
KU60019 (1-2 μM). Finally, the triple combination of 
CBD, ATMi, and γ-irradiation demonstrated a strong 
downregulation of foci formation (Figure 1A), allowing 
to maintain the DNA damage conditions. The efficiency 
of DNA repair 6 h after the initial treatment was reflected 
by a strong decrease of γ-H2AX foci formation in the 
nuclei of the control irradiated cells and small changes 
in ATMi- or (ATMi+CBD)-treated irradiated cells (data 
not shown).
Western blot analysis confirmed the specificity 
of the ATMi KU60019 (at concentration 1-2 μM) 
for suppression of γ-irradiation-induced ATM kinase 
activation in U87MG GBM cells 4 h after treatment 
(Figure 1B). As a result of this inhibition, a characteristic 
consequence of DNA-damage-induced ATM kinase 
activation, ATM-dependent Ser-15 phosphorylation, 
and stabilization of p53 protein levels [22] was also 
suppressed in GBM cells (Figure 1B). CBD treatment, 
alone or in combination with γ-irradiation strongly affects 
the activation of MAPKs, including JNK1/2, MAPK 
p38, and ERK1/2, in GBM cells [21]. We addressed a 
probable interference of ATM-mediated signaling and 
CBD-induced activation of MAP kinases. We confirmed 
previously described data that JNK1/2 phosphorylation/
activation was very strong 4 h after treatment with CBD 
and γ-irradiation, alone or, especially in combination, 
in U87MG cells (Figure 1B). Partial but significant 
suppression of JNK1/2 phosphorylation in the presence 
of KU60019 (1-2 μM) further decreased activation of JNK 
downstream targets, cJUN-P(S73) and ATF2-P(T71), in 
CBD-treated non-irradiated or irradiated GBM cells 4 h 
after treatment (Figure 1B). ATMi did not affect MAPK 
p38 phosphorylation at this time point. It should be 
mentioned that ATF2-T71 phosphorylation is directed 
mostly by JNK, rather than MAPK p38 in U87MG cells 
[21], correlating with JNK activity. On the other hand, a 
direct ATM-driven phosphorylation of ATF2-Ser490/498 
was elucidated previously that was important in the 
regulation of DNA damage response [27]. The negative 
effects of ATMi on phosphorylation of p53, JNK, 
cJUN and ATF2 were almost not pronounced 24 h after 
treatment (Figure 1C).
ERK1/2 phosphorylation was notably increased 4 h 
after γ-irradiation in the presence of ATMi, CBD or both 
and then gradually decreased 24 h after treatment (Figure 
1B and 1C). In contrast, phosphorylation-activation of 
AKT1-Ser473 was partially suppressed in the presence 
of ATMi, in both non-irradiated and irradiated U87MG 
cells 4 h and, especially, 24 h after treatment. Levels of 
phosphorylated NF-κB p65-P(S536) and total NF-κB p65 
were relatively stable 4 h - 24 h after treatment (Figure 1C).
Taken together, these results demonstrate that CBD 
treatment induces pronounced changes in activities of 
several crucial protein kinases and their corresponding 
targets in the non-irradiated and irradiated cells that 
regulate cell proliferation, survival, and death. Additional 
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modulation of these activities by cotreatment with ATMi 
in concert with simultaneous suppression of DNA repair 
could dramatically change cell fate. Although suppression 
of ATM kinase activation downregulated p53-mediated 
cell death pathways such as what in U87MG cells, it also 
opened alternative possibilities for regulation of cell death 
and survival [28, 29].
Inhibition of ATM kinase increased the death of 
GBM cells induced by combined treatment of 
γ-irradiation and CBD
Following up on the previous finding that CBD 
induced production of ROS and damaged mitochondrial 
function in human glioblastomas [14, 30, 31], we 
performed functional staining of active mitochondria with 
MitoTracker (green) to ascertain if combined treatment 
in the presence of ATMi affected normal mitochondrial 
function in U87MG cells. As shown in Figure 2A and 
2B, normal mitochondrial function in U87MG cells was 
impaired 6 h after treatment with CBD (20 μM) alone or 
in combination with γ-irradiation (at 10 Gy). On the other 
hand, a combination of CBD, ATMi and γ-irradiation (10 
Gy) negatively affected levels of mitochondrial activity 
6 h after treatment, similarly with just a combination of 
CBD and 10 Gy, indicating that the early effects of ATMi 
on mitochondria were not sufficient to significantly 
change the action of CBD and γ-irradiation.
A massive detachment of dying GBM cells and 
a lower ratio of adherent live cells with changed shape 
was observed later at 48-72 h after treatment with CBD, 
alone or in combination with irradiation [21]. Precise 
quantitative determination of cell viability (using detection 
of ATP-dependent luciferase activity in CellTiter-Glo cell 
viability assay) demonstrated dose-dependent negative 
effects of CBD (5-40 μM) on glioblastoma cell survival 
that was additionally increased by irradiation at 10 Gy. 
For CBD doses of 5-40 μM, well-pronounced additive 
effects in combination with γ-irradiation were established, 
although the highest dose of CBD used (40 μM) by itself 
Figure 1: Effects of ATM kinase inhibition on radiation response of U87MG GBM cells. (A) Effects of γ-irradiation (10 Gy), 
alone or together with cannabidiol (CBD, 10 μM in 0.1% DMSO), the ATM kinase inhibitor (ATMi) KU60019 (2 μM) in 0.1% DMSO on 
induction of DNA DSB in the nuclei of U87MG cells 0.5 h after treatment. DSB foci formation was determined using immunostaining with 
anti-H2AX-P-(S139) Ab (green) and DAPI staining of DNA (blue) that was followed by confocal microscopy. Bar = 10 μm. (B and C) 
Changes in the patterns of signaling proteins after treatment of U87MG cells with ATMi (2 μM) and CBD (20 μM), alone or in combination, 
followed by γ-irradiation at 10 Gy. CBD, ATMi and 0.1% DMSO (vehicle) were added to the cell cultures 30 min before irradiation. 
Western blot analysis of indicated signaling proteins from U87MG cells was performed 4 h and 24 h after treatments.
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dramatically decreased cell viability with relatively small 
additional effects of γ-irradiation (Figure 2C).
We used the ATMi KU60019 to further investigate 
its general effects on radiosensitization of cancer cells 
[26], alone or in combination with CBD. Treatment 
with KU60019 (1-5 μM) resulted in a modest and 
dose-dependent decrease of U87MG cell viability 48 h 
after treatment (Figure 2D). Concurrent treatment with 
γ-radiation (10 Gy) increased the toxicity in an additive 
manner (Figure 2D). Doses of 1-2 μM KU60019 were 
selected for all subsequent experiments. Cell viability 
assays demonstrated that the presence of KU60019 (2 
μM) significantly decreased the viability of U87MG cells 
48 h after combined treatment with CBD (5-20 μM) and 
γ-irradiation (Figure 2E). However, there was the absence 
of significant negative effect of KU60019 on U87MG 
viability after combined treatment with the highest dose 
of CBD (40 μM) and γ-irradiation (10 Gy) (Figure 2E). 
Hence, prolonged effects of ATM kinase inhibition 
resulted in an increase of cell killing by CBD (at low and 
intermediate doses) and γ-irradiation.
We used (Annexin-V-FITC + PI) staining of 
U87MG cells and the flow cytometry to further distinguish 
between early apoptosis (EA), late apoptosis (LA) and 
secondary necrosis (SN) 24 h and 48 h after indicated 
treatment modalities (Figure 3A and 3B). CBD (10-20 
μM) and γ-irradiation at 10 Gy effectively induced early 
and advanced phases of apoptosis in U87MG cells, while 
the presence of ATMi (KU60019) decreased CBD-induced 
apoptotic levels 48 h after treatment (Figure 3A). Figure 
3B summarized the percentage of early apoptotic (dying) 
and late apoptotic/ secondary necrotic (dead) cells 48 h 
after treatment. At this time point, the presence of ATMi 
significantly decreased apoptotic death levels induced 
by (CBD+10Gy) treatment, while total cell death levels 
were actually increased (see Figure 2E). It indicated 
Figure 2: CBD, alone or in combination with ATMi and γ-irradiation (10 Gy) decreased the viability of U87MG cells. 
(A) Effects of CBD (10 μM), ATMi (2 μM) and γ-irradiation (10 Gy) on functional activity of mitochondria in U87MG cells detected 6 h 
after treatment using Mitotracker (green) incubation and confocal microscopy. Additionally, cells were stained with anti-α-Tubulin mAb 
(red) and DNA-specific DAPI (blue). Bar = 20 μm. (B) Relative levels of Mitotracker-induced green fluorescence after indicated treatments 
of U87MG cells. Pooled results of three independent experiments 48 h after treatments are shown. Error bars represent means ±S.D. (p < 
0.05, Student’s t-test). (C-E) Effects of CBD (5-40 μM) and ATMi (1-5 μM), alone or in combination with γ-irradiation (10 Gy) on U87MG 
cell viability using the determination of intracellular ATP via ATP-dependent luminescence intensity 48 h after treatment. Combinations of 
CBD (5-20 μM), ATMi (2 μM) and γ-irradiation (10 Gy) were used in the panel E. Stars, arrows, circles, and squares indicate significant 
differences in the cell viability after specified treatments.
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that a non-apoptotic mechanism was probably involved 
in (CBD+ATMi+10Gy)-induced total cell death that 
dominated a decrease in apoptotic signaling. Only relative 
mild morphological changes were observed on confocal 
images of control and irradiated U87MG cells 24 h after 
treatment (Figure 3C).
An additional proof of apoptotic commitment, 
caspase-8 and caspase-9 activation (detected via the 
appearance of cleaved subunits) was at relatively low levels 
24 h after treatment of U87MG cells, while caspase-3 
activation (detected via the release of p17 subunit, as 
well as via caspase-3-mediated PARP-1 cleavage was 
well-pronounced (Figure 3D). Advanced apoptosis was 
observed 48 h after treatment. It was accompanied by an 
enhanced caspase-3-dependent cleavage of PARP-1 (with 
releasing the p89 cleaved subunit) after CBD treatment 
alone or with γ-irradiation. These data also demonstrated 
a decrease of levels of PARP-1 p89 cleaved subunit in the 
presence of ATMi (Figure 3E).
Effects of combined treatment on cell cycle, 
proliferation and clonogenic survival of U87MG 
cells
Next, we determined the effects of ATM inhibition, 
alone or in combination with γ-irradiation and CBD, 
on the regulation of the cell cycle, cell proliferation 
and clonogenic survival of U87MG cells. FACS 
analysis demonstrated, as expected, a strong increase 
in the percentage of G2/M-arrested cells 30 h after 
γ-irradiation, especially in the presence of ATMi (Figure 
4A). Furthermore, two combined treatment modalities 
(CBD+10Gy irradiation) or (CBD+ATMi+10Gy), 
similarly and modestly increased the percentage of pre-G1 
cells (that contained apoptotic and secondary necrotic cells) 
at 30 h (Figure 4A) and 48 h after treatment (Figure 4B). 
The percentage of GBM cells arrested at the G2/M phase 
was maximal at 48 h after treatment with (ATMi+10Gy 
irradiation), while after (ATMi+CBD+10Gy) treatment 
Figure 3: The apoptotic commitment of U87MG after treatment with CBD (10-20 μM), ATMi (2 μM) and γ-irradiation 
(10 Gy), alone or in combinations. (A and B) Annexin-V-FITC and PI staining for determination of early apoptotic (EA), late 
apoptotic (LA) and secondary-necrotic (SN) GBM cells after indicated treatment was followed by the flow cytometry. Typical experiment 
(A) and pooled results of four independent experiments (B) using U87MG cells 24-48 h after indicated treatments are shown. Percentage 
of (dying + dead cells) included early apoptotic (EA), late apoptotic (LA) and secondary necrotic cells (SN). Error bars represent means ± 
S.D. (p < 0.05, Student’s t-test). The stars and the arrows indicate significant differences between indicated cells after specified treatment. 
(C) The images of control and irradiated U87MG after immunostaining with α-Tubulin and DAPI followed by confocal microscopy are 
shown. (D and E) Western blot analysis of apoptotic marker proteins 24 h and 48 h after indicated treatments of U87MG cells.
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this ratio actually decreased with redistribution of cells 
between the pre-G1 and the G1 cell subpopulations (Figure 
4A and 4B). In general, a high ratio of irreversibly arrested 
G2/M cells after suppressing the DNA repair predicted a 
prolonged cell death via a necrotic mechanism, such as 
necrotic mitotic catastrophe.
Cell growth kinetics clearly demonstrated diverse 
suppressive effects of CBD, ATMi, γ-irradiation and 
their combinations on the growth of U87MG cell culture 
(Figure 4C). Combined treatment of U87MG cells with 
ATMi+CBD+10Gy induced rapid growth retardation, due 
to suppression of cell proliferation and increased cell death 
(Figure 4C, the bottom panel). Finally, clonogenic survival 
assay of U87MG cells revealed 70% elimination of cell 
clones by combined treatment of ATMi (2 μM) + CBD (20 
μM) in non-irradiated cells and the complete elimination 
of U87MG clones after additional γ-irradiation (at 5 Gy) 
(Figure 4D). Interestingly, a combination of [ATMi (2 
μM) + CBD (20 μM) + γ-irradiation (5 Gy)] resulted in an 
equivalent cell toxicity to [CBD (20 μM) + γ-irradiation (10 
Gy)], further indicating a radio-sensitizing role for ATMi 
in U87MG treatment (Figure 4D). These results confirmed 
the important role of ATM inhibition in the complete 
elimination of treated GBM cells. Our next task was to 
evaluate the levels of apoptotic and non-apoptotic cell death 
after combined treatment in two additional GBM cell lines.
Figure 4: Analysis of cell cycle, cell growth, and cell death following treatment of U87MG GBM with the ATMi 
inhibitor KU60019, CBD and γ-irradiation, alone or in combination. (A and B) Changes in the cell cycle and levels of death 
were determined following treatments of U87MG cells with CBD (10-20 μM), ATMi (2 μM) and γ-irradiation at 10 Gy, alone or in 
combination. Cell cycle-apoptosis analysis was performed 30 h and 48 h after indicated treatments. CBD, ATMi or their combination, as 
well as control 0.1% DMSO, were added 30 min before irradiation. The nuclei of control and treated cells were stained with PI and DNA 
content in cells was determined using the flow cytometry. The nuclei of apoptotic and secondary necrotic cells were localized in the pre-G1 
region. A typical result 30 h after treatment is shown in the panel (A). Pooled results of four independent experiments for U87MG 48 h 
after treatments are shown in panel (B). Error bars represent means ±S.D. (p < 0.05, Student’s t-test). The stars, arrows, and circles indicate 
significant differences in the pre-G1 and the G2/M levels between cells after specified treatment. (C) Kinetics of U87MG cell growth was 
monitored 0-96 h after indicated treatments: 0.1% DMSO (as control), ATMi (2 μM), CBD (10 μM), γ-irradiation (at 5 Gy), alone or in 
combination. (D) Clonogenic survival assay was performed for cell cultures after indicated treatments with 0.1% DMSO (as control), ATMi 
(1-2 μM), CBD (20 μM) or a combination of ATMi+CBD without or with γ-irradiation at 5 Gy and 10 Gy. The final number of cell clones 
was determined after 12 days of cell culture growth. A ratio of a number of clones of treated cells to a number of clones of control cells 
reflects cell survival (percentage). Stars indicate the absence of survived clones.
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Survival response of T98G and U118 GBM cells 
to combined treatment
Even though T98G GBM cells (TP53mut; 
PTENmut) are very different from U87MG GBM cells 
(TP53wt; PTENmut) in many respects, including the 
chromosome ploidy and sets of somatic mutations, there 
is a certain similarity in their response to CBD- and 
γ-irradiation treatment and the modulation on their cell 
signaling pathways after cotreatment with ATMi (Figure 
5). Similarly to U87MG cells, γ-irradiation effectively 
induced γ-H2AX foci formation in the nuclei of T98G 
cells that was substantially blocked by ATMi (Figure 5A). 
Furthermore, ATMi prevented p53-(S15) phosphorylation 
and downregulated its protein levels in irradiated cells 
(Figure 5B). JNK activation by CBD in T98G cells 
was pronounced but somewhat decreased, compared 
to its activity in U87MG cells (see Figures 5B and 1B). 
A strong activation of MAPK p38 by CBD was also 
detectable in T98G cells followed by activation of ATF2 
via Thr-71 phosphorylation, which could be suppressed 
in the presence of ATMi. Suppression of AKT1 activity 
in the presence of ATMi was also revealed. ERK2-P and 
NF-κB p65-P levels were relatively stable after treatment 
(Figure 5B). Numerous effects of ATMi on the crucial cell 
signaling pathways predict its modulating effects on cell 
growth and survival following treatment of T98 cells with 
CBD and γ-irradiation.
Figure 5: Changes in the pattern of cell signaling proteins of T98G human GBM cells and regulation of cell death 
after treatment with ATMi alone or in combination with CBD and γ-irradiation. (A) DNA DSB were induced in the nuclei 
of treated T98G cells and detected by immunostaining with anti-γH2AX Ab (green foci) and DAPI staining of DNA (blue). (B) Western 
blot analysis of indicated signaling proteins from T98G cells was performed 4 h after treatments with CBD (10 μM), the ATMi KU60019 
(2 μM), alone or in combination, without or with γ-irradiation (10 Gy). CBD, ATMi, and DMSO (a vehicle) were added to the cell cultures 
30 min before irradiation. (C and D) Apoptotic levels in T98G cells were detected using Annexin-V-FITC and PI staining, as described 
in Figure 3A. A typical result (C) and the pooled results of four independent experiments are presented (D). Error bars represent means ± 
S.D. (p < 0.05, Student’s t-test). The arrows and circles indicate significant differences in cell death levels between control cells and cells 
after specified treatments.
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The “gain of function” of mutated p53 resulted in 
additional resistance to temozolomide-induced apoptosis 
in T98G cells [32]. Nevertheless, (CBD+10Gy)-induced 
apoptosis was pronounced, while the presence of ATMi 
partially decreased pro-apoptotic and secondary necrotic 
levels induced by CBD at the 10-20 μM in non-irradiated 
and irradiated cells (Figure 5C and 5D). Surprisingly, the 
pre-G1 levels after treatment with ATMi+CBD+10Gy were 
actually increased in T98G cells, compared to treatment 
with CBD+10Gy, demonstrating the additive effect (Figure 
6A and 6B). Inhibitory effects of combined treatments 
on cell proliferation were also highly detectable and 
especially strong for treatment with the triple combination 
of ATMi+CBD+10Gy (Figure 6C). For clonogenic 
survival, a combination of ATMi (2 μM), CBD (20 μM) 
and γ-irradiation (5 Gy) caused complete elimination of 
clones of GBM cells 12 days after treatment (Figure 6D). 
Furthermore, γ-irradiation at 10 Gy completely eliminated 
T98G clones pre-treated with [ATMi (1μM) + CBD 
(20μM)] or ATM (2μM), demonstrating higher efficiency 
of ATMi for radiosensitization of T98G cells.
The results of our study on U118MG cell death also 
demonstrated strong effects of γ-irradiation, ATMi, and 
CBD, alone or in combination, on upregulation of cell 
percentage at G2/M phase but moderate effects on levels of 
apoptosis (Supplementary Figure 1). Modulation of p53-
P(S15) levels in non-irradiated and irradiated cells in the 
presence of ATMi was easily detectable (Supplementary 
Figure 1E). Paradoxically, this cell line demonstrated very 
low levels of JNK activation upon CBD treatment [21], 
Figure 6: Cell cycle analysis, growth and clonogenic survival of T98G cells after treatments with indicated combinations 
of cannabidiol (CBD), the ATMi KU60019 and γ-irradiation (5-10 Gy). (A and B). Cell cycle-apoptosis was performed 30-48 h 
after indicated treatments of T98MG cells with CBD (10 μM), ATMi (2 μM), and γ-radiation (10 Gy). CBD and ATMi, as well as a vehicle 
control (0.1% DMSO), were added 30 min before irradiation. Cells were stained with PI for determination of DNA content using the flow 
cytometry. A typical result is shown in the panel (A). Pooled results of four independent experiments for T98G cells 48 h after treatments 
are shown in panel (B). Error bars represent means ±S.D. (p < 0.05, Student’s t-test). The stars, arrows, and circles indicate significant 
differences in the percentages of the pre-G1 or the G2/M cell populations after indicated treatments. (C) Kinetics of T98MG cell growth 
was monitored 0-96 h after indicated treatments: 0.1% DMSO (as control), ATMi (2 μM), CBD (10 μM) or a combination of ATMi+CBD 
without and with γ-irradiation. (D) Clonogenic survival assay was performed for cell cultures after indicated treatments with 0.1% DMSO 
(as control), ATMi (1-2 μM), CBD (20 μM) or a combination of ATMi+CBD followed by γ-irradiation. The final number of cell clones was 
determined after 12 days of cell culture growth. A ratio of a number of clones of treated cells to a number of clones of control cells reflected 
cell survival (percentage). Stars indicate the absence of survived clones.
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while ERK1/2, MAPK p38, and AKT exhibited strong 
and stable activities (Supplementary Figure 1E). However, 
the triple combination of ATMi+CBD+10Gy moderately 
downregulated AKT1-P(S473) levels 4 h after treatment 
(Supplementary Figure 1E), with a substantial decrease of 
these levels at 24 h after treatment (not shown) allowing 
to partially suppress anti-apoptotic response. Finally, the 
clonogenic survival assay demonstrated the complete 
elimination of cancer cell clones 12 days after treatment 
with the triple combination of ATMi (2 μM), CBD (20 
μM) and γ-irradiation at 5 Gy.
Taken together, our data showed relatively similar 
features in upregulation of total cell death for three 
human GBM lines 12 days after treatment with a triple 
combination of killing factors, even though a role of 
apoptotic and non-apoptotic stimulation was different 
and cell-specific. The comprehensive comparison of cell 
viability for three GBM lines (using detection of ATP-
dependent luciferase activity in CellTiter-Glo cell viability 
assay) further confirmed strong suppressive effects of the 
triple combination of 20 μM CBD, γ-irradiation at 10 Gy 
in and ATMi (2 μM) for the dramatic and almost complete 
elimination of GBM cells even 48 h after treatment 
(Figure 7). On the other hand, prolonged incubation of 
treated cells after the triple combination of CBD (20 μM), 
ATMi (2 μM) and a lower dose of γ-irradiation (5 Gy) also 
resulted in complete elimination of GBM clones 12 days 
after treatment as was observed in clonogenic survival 
assay (see Figures 4D, 6D and Supplementary Figure 1F).
Secretory phenotypes of GBM cells after 
treatment by CBD, γ-irradiation, and ATMi: 
expression of pro-inflammatory cytokines
Endogenous and microenvironment-induced 
synthesis of pro-inflammatory cytokines is a characteristic 
feature of many different types of advanced cancers, 
including glioblastoma, especially after stress treatments 
[33]. In the current study, we addressed the regulation 
of transcription and protein expression of several pro-
inflammatory cytokines (IL-1β, IL-6, and IL-8) by CBD, 
ATMi and γ-irradiation, alone or in combinations, in 
U87MG GBM cells (Figure 8) that could be critically 
important for in vivo conditions. Only modest changes in 
specific mRNA levels of these cytokines were observed at 
4 h after treatment, while moderate changes were observed 
24 h after treatment (data not shown). Finally, dramatic 
changes in transcription levels of the IL-1β, IL-6 and IL-8 
mRNA occurred between 24 h and 48 h after the initiation 
of treatment by CBD alone or, especially, in combination 
with γ-irradiation (Figure 8A). ATMi in combination with 
(CBD+10Gy) additionally increased these levels for IL-1β, 
Figure 7: Effects of CBD (20 μM), ATMi (2 μM), and γ-irradiation (10 Gy), alone or in combination on GBM cell 
viability. Cell viability assay (based on ATP-dependent luminescence intensity 24-48 h after indicated treatments) was performed for three 
glioblastoma lines after indicated treatments. Pooled results of four independent experiments 24-48 h after treatments are shown. Error 
bars represent means ±S.D. (p < 0.05, Student’s t-test). Arrows, circles, and squares (open and black) indicate significant differences in cell 
viability after specified treatments.
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IL-6, and IL-8 48 h after treatment: the total normalized 
increase was at 200-fold for IL-1β and IL-8 while at 60-
fold for IL-6, compared to the control levels (Figure 8A). 
In contrast, TGFβ1 levels were relatively stable (data not 
shown). Precise mechanisms that involved in dramatic 
upregulation of transcription of several cytokines by 
indicated combinations of treatment modalities need an 
additional investigation. However, strong inhibitory effects 
of small molecule inhibitors BMS344551 (IKK-NF-κB) 
and LY294002 (PI3K-AKT-NF-κB) on basal and (CBD + 
γ-irradiation)-induced levels of these cytokines (data not 
shown) highlights a critical role of permanently active NF-
κB in regulating of basal expression of proinflammatory 
cytokines IL-1β, IL-6 and IL-8 [33].
Besides the indicated pro-inflammatory cytokines, 
the expression of the immunosuppressor FAS-L was 
detected in U87MG glioblastoma cells (Supplementary 
Figure 2A). Fas-L mRNA levels were strongly increased 
following CBD or CBD+ATMi treatment, likely due 
to JNK-cJUN/ATF2 upregulation since transcription 
factor AP1 (cJUN-ATF2) is a critical regulator of FAS-L 
expression [34] among other transcription factors. It was 
followed by a moderate CBD-mediated increase of FAS-L 
protein levels that was more pronounced in non-irradiated 
cells (Supplementary Figure 2B). Furthermore, the 
total protein and surface levels of FAS-receptor notably 
increased after irradiation (Supplementary Figure 2C), 
potentially allowing the paracrine/ autocrine mechanism of 
FAS-L/FAS-mediated apoptosis in glioma cells. However, 
endogenous FAS-L-mediated apoptosis was not detected 
at pronounced levels in U87MG cells [21]. In contrast, 
FAS-L expression and secretion might be potentially 
Figure 8: CBD-mediated control of pro-inflammatory cytokines and DR5/TRAIL-R2 in U87MG cells. (A and B) Gene 
expression of pro-inflammatory cytokines (IL1β, IL6, and IL8), as well as TRAIL-R2 in U87MG cells, was determined by quantitative real-
time PCR. mRNA was isolated 48 h after treatment with 0.1% DMSO (control vehicle), CBD (10 μM), ATMi (2 μM) and γ-irradiation (10 
Gy) alone or in combination. The graphs indicate the fold change of target gene mRNA levels against time-point control after normalized 
to the reference gene (beta-ACTIN). The pooled results of four independent experiments are presented. Error bars represent means ± 
S.D. (p < 0.05, Student’s t-test). (C) Effects of CBD (10 μM) and γ-irradiation (10 Gy) on surface expression of DR5/TRAIL-R2 were 
determined using immunostaining and FACS analysis. Median fluorescent intensity is shown in square brackets. (D) Effects of pretreatment 
(18 h) with CBD (20 μM), ATMi (2 μM) and their combination on apoptosis of U87MG cells induced by exogenous TRAIL (50 ng/ml) + 
cycloheximide (1 μg/ml). Apoptosis-cell cycle analysis of U87MG cells was performed and the percentage of pre-G1 (apoptotic) cells was 
determined using flow cytometry. The pooled results of three independent experiments are presented. Error bars represent means ± S.D. (p 
< 0.05, Student’s t-test). (E) Microscopic view of cell death induced by exogenous TRAIL (50 ng/ml) or by pretreatment (18 h) of CBD (20 
μM) followed by treatment with TRAIL (50 ng/ml for 24 h)
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important for immune surveillance in GBM [35]. CBD 
treatment did not notably affect permanently active NF-
κB levels in glioblastoma cells (Figures 1C and 5B).
Another signaling pathway that could play an 
essential role in GBM cell death under stressful conditions 
is TRAIL-TRAIL-R2 (21). The endogenous expression of 
TRAIL in both U87MG and U118MG GBM lines was 
low and only modestly increased after irradiation (data not 
shown). An alternative possibility for increasing TRAIL-
induced apoptosis in GBM cells was CBD-induced 
upregulation of gene, protein and cell surface expression 
of TRAIL-R2/DR5 (Figure 8B and 8C) and use of the 
exogenous TRAIL for induction of apoptosis. Indeed, pre-
treatment with CBD, ATMi or combination of CBD+ATM 
for 18 h followed by treatment with the exogenous TRAIL 
(50 ng/ml) resulted in high levels of TRAIL-mediated 
apoptosis after subsequent 24 h of incubation (Figure 8C 
and 8D).
PD-L1 expression in U87MG cells following 
CBD treatment and γ-irradiation
A strategy of glioma gene- and epigenetic regulation 
directed by the Darwinian clonal selection during 
carcinogenesis is tightly linked with the acquisition of 
immunosuppressive functions of cancer cells, including 
boosted FAS-L, PD-L1 and PD-L2 expression, their proper 
posttranslational modifications and protein trafficking to 
the cell surface. Beside FAS-L/FAS, the interaction of PD-
L1 of cancer cells with the PD1 receptor on the surface of 
CD8+ T-lymphocytes is a critical reaction of the immune 
checkpoint resulting in functional loss of anti-cancer 
activity of CD8+ T-lymphocytes [36].
We observed that CBD alone did not notably 
affect PDL1 transcription in U87MG cells (1-24 h after 
treatment), while γ-irradiation alone or in combination 
with CBD only slightly increased PDL1 mRNA levels 
(Figure 9A). BMS345541, a small molecule inhibitor of 
IKK-NF-κB marginally downregulated PDL1 transcription 
1-18 h after treatment and exhibited a variable inhibitory 
effect for the basal PD-L1 transcription (Figure 9A and 
9B). Interestingly, BMS345541 substantially increased 
radiation-induced PD-L2 expression. In contrast, 
BMS345541 suppressed both the basal and radiation-
induced levels of DR5/TRAIL-R2 that was used as a 
control target (Figure 9B). Three PD-L1 protein species 
with the apparent molecular weight of 33-37, 55-57 
and 68-70 kD were revealed in U87MG cells (Figure 
9C). The major species, gp70 and gp57, were stable 
glycoproteins localized on the plasma membrane [37]; the 
minor non-modified p37 subunit was hardly detectable 
(or sometimes undetectable) in glioma cells (Figure 9C 
and 9D). Pretreatment with a small molecule inhibitor 
BMS345541 (but not SP600125 and LY294002) modestly 
decreased levels of gp70 (Figure 9C). In contrast, CBD 
treatment alone or in combination with γ-radiation notably 
decreased protein levels of gp70 and gp57 (Figure 9C), 
likely through modulation of their stability by CBD-
activated kinases linked with the proteasome system 
[37]. Levels of surface expression of PD-L1 were also 
under negative control of CBD: immunostaining and the 
flow cytometry demonstrated increased levels of PD-
L1 surface expression after γ-irradiation, but decreased 
level after treatment with CBD alone or in combination 
with radiation 24 h after treatment (see a decrease of the 
percentage of cells with high surface expression of PD-L1 
on Figure 9E).
Taken together, our results show pronounced but 
mild negative effects of CBD on PD-L1 gene/protein/cell 
surface expression, in sharp contrast to CBD-mediated 
positive effects on DR5/TRAIL-R2 expression (see Figure 
8), highlighting the critical features of an anti-cancer 
strategy driven by CBD.
Effects of CBD, alone or in combination with 
γ-irradiation and ATMi on the viability of 
U87MG neurospheres
In spite of a restricted similarity between primary 
GBM cells in vivo and established cell lines after many 
passages in culture conditions (such as U87MG, U118MG 
and T98G glioblastoma lines), a recent comprehensive 
study highlighted the importance of established cell lines 
that represent relatively similar patterns of gene alteration 
as cancer cells in vivo [38]. On the other hand, glioma 
spheroid cultures are considered to be a source of glioma 
stem-like cells (glioma-initiating cells) that are especially 
resistant to treatment, including γ-irradiation [39, 40]. In 
general, patient-derived glioma stem-like cells grown in 
neural stem cell culture as neurospheres may retain most 
of genomic and epigenetic characteristics of primary 
patient tumors, thus representing an additional model 
system in glioma investigation [41]. U87MG spheroid 
culture enriched by CD133+ glioma stem-like cells was 
established as described in “Materials and Methods” and 
in our previous publication [42]. Increasing complexity of 
treatment using CBD (10 μM), [CBD (10 μM) + 10 Gy] 
and [CBD (10 μM) + 10 Gy + ATMi (2 μM)] resulted in the 
progressive decline of viability of U87MG neurospheres, 
revealed by several different approaches: phase-contrast 
microscopy, cell viability assay and immunostaining 
with anti-CD133 mAb (Figure 10A-10C). Even the 
viability of U87MG neurospheres after treatment was 
higher compared to the corresponding adherent culture, 
providing data on the sensitivity of glioma neurospheres 
to CBD, alone or in combination, which look promising 
for suppression of cancer growth. These observations that 
extended recently published data on treatment of U87MG 
glioma-initiating cells by a combination of CBD, THC 
and temozolomide [43] still required additional studies 
for confirmation of the efficacy of a used combination 
through treatments in vivo.
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CBD-mediated effects on human TS543 
proneural glioma cells
Further progress of our study was linked with 
an additional investigation using combined treatment 
on the human TS543 (PDGF+) proneural glioma 
cell line at a low passage, which also could be grown 
either as neurospheres (Figure 11) or adherent cells. 
TS543 neurospheres were extremely sensitive to CBD, 
demonstrating dose-dependent response (Figure 11A) 
24-48 h after treatment and resulting in a complete 
elimination of live cells after treatment with 40 μM CBD 
(Figure 11B). Additional 30-min incubation of control and 
CBD-treated cells (48 h) with CellTracker green (#C7025 
from “Invitrogen”) and confocal microscopy also revealed 
CBD-mediated damage of neurospheres and a strong 
downregulation of cell viability (Figure 11C). CBD-
mediated radiosensitization, especially in the presence of 
ATMi, was detected for intermediate levels of CBD (10-20 
μM) (Figure 11B).
Figure 9: Gene and protein expression and surface levels of PD-L1 after treatment with CBD, alone or in combinations. 
(A and B) The quantitative real-time PCR analysis of the PD-L1, PD-L2 and DR5 mRNA levels 1-24 h after treatments of U87MG by 
CBD (10 μM), BMS345541 (20 μM), LY294002 (40 μM) and γ-irradiation (5-10 Gy), alone or in combination. The graphs indicate the 
fold change of target gene mRNA levels against time-point control after normalized to the reference gene (beta-ACTIN). The pooled 
results of four independent experiments are presented. Error bars represent means ± S.D. (p < 0.05, Student’s t-test). Black stars, black 
and open circles, arrows and squares indicate a significant difference in mRNA levels between control and specifically treated cells. (C 
and D) Western blot analysis of PD-L1 protein expression after CBD (10-20 μM) treatment, alone or in combination with SP600125 (20 
μM), BMS345541 (20 μM), LY294002 (40 μM), ATMi (2 μM) and γ-irradiation (10 Gy) in U87MG cells. (E) Negative effects of CBD on 
PD-L1 surface expression in non-irradiated and irradiated (10 Gy) cells were determined using immunostaining and the flow cytometry. 
Percentage of gated cells (with high and low expression) is indicated. Median fluorescent intensity is indicated in the brackets.
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To further extend our observation on CBD-mediated 
death for proneural glioma cultures at a low passage, we 
took advantage of two mouse glioma lines created in the 
laboratory of Dr. P. Canoll (Columbia University, New 
York): PPG2 (Pdgf+, p53−/−, Pten+/+) and MGPP3 
(Pdgf+, p53−/−, Pten−/−). MGPP3 represents a mouse 
proneural glioma cell line [44, 45]. Both cell cultures 
could grow either as neurospheres in suspension culture 
or as adherent cells in laminin-treated plates. One of 
the critical targets of CBD in human and mouse GBM 
used in the current study was the PI3K-AKT pathway 
(see Figures 1B and 5B). A series of experiments were 
performed with mouse glioma cells grown as neurospheres 
(Figure 11D). Due to Pten knock-out and the subsequent 
PI3K-AKT over-activation in MGPP3 cells, there was 
a substantial decrease in sensitivity to CBD, alone or in 
combination with γ-irradiation for this line, compared 
to PPG2 (Figure 11D). Pretreatment with ATMi (2 μM) 
and γ-irradiation (5 Gy) that targeted numerous signaling 
pathways, including PI3K-AKT, further decreased the 
survival of the CBD-treated MGPP3 neurosphere culture. 
Additionally, significant levels of CBD-induced apoptotic 
death (as % cells in pre-G1 area) were revealed in MGPP3 
adherent cell culture 24 h after treatment. As expected, 
the corresponding death levels in PPC2 cells were higher 
(Figure 11E).
Taken together, our results demonstrated the ability 
of CBD to partially overcome GBM resistance to treatment, 
even in the case of PI3K-AKT over-activation, which was a 
critical component of this resistance pathway [46].
DISCUSSION
Glioblastoma (GBM) is a hallmark of cancer 
resistance to treatment, including radioresistance and 
cancer-associated immunosuppression. Despite aggressive 
Figure 10: Induction of cell death in U87MG spheroid cultures following treatments with CBD, ATM inhibitor (ATMi), 
and γ-irradiation (10 Gy), alone or in combination. (A) Phase-contrast images of U87MG neurospheres 48 h after treatment 
with 0.1% DMSO (control) or CBD (10 μM), alone or in combination with γ-irradiation (10 Gy) or γ-irradiation + ATMi (2 μM). (B) 
Cell viability assay was performed for U87MG neurosphere cultures 48 h after indicated treatments. Pooled results of four independent 
experiments 48 h after treatments are shown. Error bars represent means ±S.D. (p < 0.05, Student’s t-test). Arrows and stars indicate 
significant differences in cell viability after specified treatments. (C) U87MG neurospheres from suspension cultures (72 h after treatment) 
were attached to coverslips and immunostained with anti-CD133 mAb (green).
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therapies, the prognosis for GBM patients remains dismal. 
Identification of novel pharmacological targets and 
development of new therapeutic strategies are urgently 
needed. There are several potentially efficient approaches 
among others used for GBM trials to overcome, at least 
partially, extremely damaging effects of cranial irradiation 
and chemotherapy and substantially increase a selectivity 
for killing of brain cancer cells: 1) the precise external 
beam radiation therapy by Gamma Knife radiosurgery 
that allows minimization of radiation-induced necrosis 
to surrounding brain tissue [47]; 2) application of small 
molecule inhibitors of the specific signaling pathways, 
which are overactive in the particular glioblastoma type; 
and 3) advanced immunotherapy of cancer [48, 49].
A complementary possibility for advanced GBM 
treatment is the activation of cell signaling receptors, 
which could regulate gene expression controlling cell 
death specifically in cancer cells rather than in non-
malignant cells. Cannabinoid receptor CB1 is the most 
abundant cell surface receptor in the brain; cannabinoid 
receptor CB2 is also widely expressed in different types 
of cells, including both normal glial cells and GBM [50]. 
Both receptors, by binding endocannabinoids, activate 
signaling cascades, which control proliferation, survival 
and other normal functions. Dysregulation of cannabinoid-
mediated signaling that tightly linked with the COX2-
dependent production of prostaglandin-E2 is one of the 
leading strategies of the clonal selection during glioma 
Figure 11: The viability of TS543 human glioma spheroid cultures following treatments with CBD, ATM inhibitor 
(ATMi), and γ-irradiation (5 Gy), alone or in combination. (A) Dose-dependent response of TS543 neurospheres to CBD (0-40 
μM). (B) Combined treatment of neurospheres using CBD, γ-irradiation (5 Gy) and ATMi (2 μM). Cell viability assay was performed for 
TS543 neurosphere cultures 24-48 h after indicated treatments. Pooled results of four independent experiments 24-48 h after treatments 
are shown. Error bars represent means ±S.D. (p < 0.05, Student’s t-test). Stars and squares indicate significant differences in cell viability 
after specified treatments. (C) CBD-treated (48 h) and control TS543 neurospheres were additionally incubated with CitoTrucker green 
for 30 min and analyzed using fluorescent microscopy. (D) Effects of CBD (5-10 μM), ATMi (2 μM) and γ-irradiation (5 Gy), alone or 
in combination, on the viability of mouse MGPP3 and PPC2 glioma neurosphere cultures 24 h after treatment. Pooled results of four 
independent experiments are shown. Error bars represent means ±S.D. (p < 0.05, Student’s t-test). Arrows and stars indicate significant 
differences in cell viability after specified treatments. (E) Effects of CBD (10 μM) and γ-irradiation (5 Gy) on pre-G1 (apoptotic) levels 
in MGPP3 and PPC2 glioma cells (adherent culture) 24 h after treatment. Cells were pretreated with 0.1% DMSO (control) or CBD 30 
min before irradiation. The nuclei of control and treated cells were stained with PI and DNA content in cells was determined using flow 
cytometry.
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carcinogenesis [51]. Paradoxically, it also provides a 
possibility for induction of GBM cell death by exogenous 
cannabinoid treatment. Numerous investigations in the last 
decade demonstrated cytotoxic effects of cannabinoids 
on human and mouse glioblastoma cells expressing both 
CB1 and CB2 receptors [12, 16, 19, 52, 53]. However, a 
specificity of the signaling mechanisms involved in the 
regulation of GBM cell death by cannabinoids is still 
not completely investigated. In previously published 
studies, we and others elucidated the effects and probable 
mechanisms of radiosensitization of GBM cells using 
cannabinoids [19–21].
From the numerous members of the cannabinoid 
family, we were focused on actions of cannabidiol (CBD) 
without psychogenic activity, alone or in combination with 
γ-irradiation, establishing a promising combination for 
induction of cell death via apoptosis or necrosis in human 
GBM cells. The main goals of our current study were: 
1) further increase efficiency of killing of human GBM 
cells by combined treatment of CDB and γ-irradiation 
using additional suppression of ATM kinase activity; 
2) elucidate a relative input of apoptotic and necrotic 
mechanisms following treatment of GBM cells with a 
triple combination of CBD, ATMi, and γ-irradiation; 
3) investigate effects of γ-radiation and CBD, alone or 
in combination, on the regulation of DR5/TRAIL-R2 
expression in glioma cells; 4) elucidate signaling 
pathways and their corresponding targets, which control 
the expression of PDL1 in glioma cells before and after 
treatment with CBD and γ-irradiation. Such data could be 
critical for the subsequent in vivo animal experiments.
Based on the results of the present study, we were 
able to further increase cytotoxic effects of combined 
treatment of CBD at intermediate (10-20 μM) doses 
and γ-irradiation (5-10 Gy) by inhibition of ATM kinase 
activity using a small molecule inhibitor KU60019. It 
caused a relatively minor downregulation of (CBD + 
γ-irradiation)-induced apoptosis simultaneously with a 
strong upregulation of a ratio of the G2/M-arrested glioma 
cells that finally blocked glioma cell proliferation. Two 
recent publications also described the strong negative 
effects of new ATM kinase inhibitors combined with 
γ-irradiation on glioma cells and GBM development [54, 
55].
The mechanism of natural surveillance and killing 
of cancer cells based on the continuous maintenance 
of the strong and specific immune response has been 
successfully used in the recent strategy of immunotherapy, 
due to the introduction of immune checkpoint inhibitors, 
including inhibitory antibodies to PD1 or its ligand PD-
L1, which is often overexpressed by cancer cells [56–58]. 
Unfortunately, this variant of immunotherapy successfully 
works only in six types of immunologically “hot tumors”: 
bladder cancer, head and neck cancers, kidney cancer, liver 
cancer, melanoma, and non-small cell lung cancer. The 
challenging problem is to apply immunotherapy for cancers 
that are immunologically “cold”, such as glioblastomas, 
ovarian, prostate, and pancreatic tumors [36].
There are, however, significant problems in 
the application of immunotherapy for brain tumor 
treatment, such as the blood-brain barrier and multiple 
well-pronounced immunosuppressive mechanisms, 
including FAS-Ligand expression by GBM that could 
induce FAS-L/FAS-mediated apoptosis of immune 
lymphocytes in the brain [35], as well as triggering 
T-lymphocyte checkpoints by PD-L1 surface expression 
in GBM cells and an additional permanent expression of 
immunosuppressors TGFβ1 and TGFβ2 by GBM cells 
[59, 60]. Interestingly, we observed dramatic upregulation 
of FAS-L expression in U87MG glioblastoma cells during 
the apoptotic commitment of these cells induced by 
CBD (see Supplementary Figure 2A and 2B), even the 
role of FAS-L/FAS-mediated suicide of GBM cells was 
not critical, due to a low endogenous expression of FAS 
Receptor [36].
One of the critical questions linked with a possible 
application of CBD or CBD+ATMi as anti-glioma agents 
was about their modulating effects on PDL1 gene-, 
protein- and surface expression. The classical pathway 
that activates PDL1 gene expression is mediated by 
interferon-γ produced and secreted by natural killers and 
CD8+ T-lymphocytes [36]. Since the PDL1 promoter 
contains four potential NF-κB-binding sites, two STAT3-
binding sites and potential AP1- and NF-AT-binding sites, 
a role of EGFR kinase activation, as well as IKK-NF-κB, 
AKT-NF-κB, JAK2-STAT3 and MAPK-AP1 activating 
pathways in the regulation of PDL1 gene expression was 
highlighted [61–65]. Furthermore, a role of radiotherapy 
in the upregulation of PD-L1 expression was also 
established [65, 66]. Our observations revealed relatively 
minor negative effects on CBD and γ-irradiation PD-
L1 gene- and protein expression in U87MG GBM cells, 
demonstrating an additional advantage of CBD treatment 
for this type of cancer.
In contrast, substantial upregulation of gene, protein 
and surface expression of DR5/TRAIL-R2 after CBD 
treatment, alone or in combination with irradiation, further 
sensitize GBM cells to the external TRAIL-induced 
apoptosis (see Figure 8). Recent attempts to use neural 
stem/progenitor cells, which express TRAIL, as vehicles 
to kill TRAIL-R2-positive GBM cells demonstrated 
promising results [67]. On the other hand, pre-clinical 
testing imipridone ONC201 for cancer treatment revealed 
several similar mechanisms with CBD-mediated induction 
of cell death [68, 69], such as targeting mitochondria and 
AKT/ERK inactivation linked with TRAIL/TRAIL-R-
mediated apoptosis.
Furthermore, we observed the enhanced secretory 
phenotype of cancer cells with massive production of 
pro-inflammatory cytokines, IL1β, IL6 and IL8, as well 
as death ligands, FAS-L and TRAIL, after combined 
treatment of GBM cells. Besides its general pro-
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inflammatory function, IL6, which is a widely-distributed 
cytokine in the nervous system, is critically important 
for glial differentiation of normal neural precursor cells 
and adult glioma differentiation of glioma stem-like cells 
[70, 71]. Potentially, CBD-induced activation of IL6 
expression in stress conditions might promote the viability 
and differentiation of a small population of glioma stem-
like cells that were resistant to killing agents used [72]. We 
also observed a protective effect of IL6 for (CBD + 5Gy)-
induced apoptosis in the whole population of U118MG 
cells [21].
However, the challenging question regarding local 
and systemic effects of CBD alone or in combination 
with γ-irradiation on the immune system needs additional 
investigations, since CBD is also known as an inducer 
of cell death of immune cells and modulator of cytokine 
production in monocytes [73, 74]. On the other hand, the 
killing of tumor-infiltrating macrophages by CBD appears 
a promising therapeutic strategy in advanced tumors where 
macrophages exhibit protumorigenic functions [73, 75].
Clinical trials with cannabinoids for GBM treatment 
have been very restricted, even providing some optimistic 
preliminary results [2, 76, 77]. Unfortunately, there are 
no available data from large, placebo-controlled trials 
regarding the systemic anti-cancer effect of cannabinoids. 
The first clinical pilot study published several years ago 
demonstrated that intracranially administered THC was 
safe in recurrent GBM patients [78]. A recently publicized 
phase II, a placebo-controlled clinical trial with recurrent 
GBM patients, provides promising data for the potential 
efficacy of cannabinoids as adjuvant anti-cancer drugs. In 
this study, 12 patients were randomized to a combination of 
THC and CBD in addition to dose-intensive temozolomide, 
whereas the remaining 9 patients were randomized to 
placebo plus temozolomide. The proof of concept study 
showed a significantly higher one-year survival rate in the 
cannabinoid group (83% versus 53% in the placebo cohort). 
Furthermore, the median survival for the cannabinoid group 
was greater than 550 days compared with 369 days in the 
group randomized to placebo (GW Pharmaceuticals 2017 
press release; https://www.clinicaltrials.gov/ Identifiers: 
NCT01812616, NCT01812603). Several ongoing clinical 
trials for newly-diagnosed GBM patients are studying 
the role of cannabinoids and results are pending (https://
www.clinicaltrials.gov/ Identifiers: NCT03529448, NCT 
03246113).
In the present study, we used combined treatment 
of CBD, as an apoptotic inducer in GBM, and γ-radiation 
together with the ATM inhibitor KU60019 for induction 
of irreversible G2/M arrest accompanied by necrosis. In 
summary, we conclude that radiation-induced death of 
several human and mouse GBM lines in culture conditions 
(including cultures of neurospheres) could be substantially 
enhanced by CBD-mediated signaling in concert with 
ATM-kinase inhibition, via both apoptotic and non-
apoptotic death pathways. We observed these death-
inducing effects not only in the “old” classical cultures 
of human GBM (U87MG, U118MG and T98G) but also 
in more recently established human TS543 and mouse 
proneural glioma lines at a low passage. Potentially, these 
data could improve the therapeutic ratio of GBM and 




ATM kinase inhibitor (ATMi) KU60019, PI3K 
inhibitor LY294002, IKK inhibitor BMS345541, MAPK 
p38 inhibitor SB203580 and JNK inhibitor SP600125 
were purchased from Calbiochem (La Jolla, CA, USA). 
Human soluble Enzo Killer-TRAIL (recombinant #ALX-
201-073-C020) and anti-human TRAIL Ab (#ALX-210-
732) were purchased from Enzo Life Sciences (San Diego, 
CA, USA). Cannabidiol (exempt preparation; #90081) 
was obtained from Cayman Chemical (Ann Arbor, MI).
Glioma cell lines
Three lines of human glioblastoma (GBM) 
were obtained from the ATCC: i) U87MG (HTB-14): 
very tumorigenic, highly invasive, highly rearranged 
hypodiploid with several hundred mutations, TP53wt, 
PTENmut; ii) U118MG (HTB-15): tumorigenic, 
moderate invasive; several hundred mutations, TP53mut, 
PTENmut; iii) T98G (CRL-1690): non-tumorigenic; 
moderate invasive, highly rearranged hypopentaploid/ 
hypohexaploid, several hundred mutations, TP53mut, 
PTENmut [79, 80]. There are some contradictions about 
the origin and maintenance of the U87MG (HTB-14) 
glioma cell line in the ATCC [81]; however, they do not 
interfere with the results of the present study. All GBM 
lines were cultured as previously described in DMEM 
with 10% FBS and 1% pyruvate [82]. For neurosphere 
formation, U87MG glioblastoma cells were cultured in the 
serum-free media DMEM/F12 supplemented with 2 mM 
GlutaMAX, bFGF (20 ng/ml), EGF (20 ng/ml) and B27 
supplement (2%). All reagents were obtained from Gibco/
Life Technologies (Carlsbad, CA, USA). After 15-20 
passages, U87MG neurosphere culture was significantly 
enriched by CD133+ cells. Additionally, human TS543 
proneural glioma cell line at low passage was grown as 
neurosphere culture [83] using in vitro proliferation kit 
for human neural stem cells NeuroCult NS-A (StemCell 
Technology, #05751) supplemented with heparin (2 μg/
ml), human bFGF (10 ng/ml) and human EGF (20 ng/ml). 
Mouse glioma lines PPG2 (Pdgf+, p53−/−, Pten+/+) and 
MGPP3 (Pdgf+, p53−/−, Pten−/−) were generated by Dr. 
Peter D. Canoll (Columbia University, New York, NY). 
These cells were cultured as previously described using 
the protocol from Dr. Peter Canoll laboratory [44, 45].
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Immunocytochemistry analysis
To label active mitochondria, live glioblastoma cells 
were incubated with MitoTracker Green FM (Molecular 
Probes #M7514) using on Invitrogen Molecular Probes 
protocol. Cells were fixed with 4% paraformaldehyde 
in PBS for 30 min. Then immunochemical staining was 
performed using standard protocols. Glioblastoma cells 
were stained with α-Tubulin (mAb #T5168 from Sigma) 
and phospho-Histone H2A.X Ser139 (mAb #05-636 from 
Millipore), as well with anti-CD133 (mAb #64326 from 
Cell Signaling Technology). The secondary Abs were 
Alexa Fluor 594 goat anti-mouse IgG from Molecular 
Probes/Life Technologies (Carlsbad, CA, USA). A Nikon 
A1 scanning confocal microscope on an Eclipse TiE 
microscope stand (Nikon Instruments, Melville, NY) 
was used for immunofluorescence image acquisition (as 
Z-series projection) and analysis. Images were further 
analyzed and quantified using ImageJ software (NIH).
Irradiation procedures
To determine sensitivity to γ-irradiation, plated cells 
were exposed to radiation from a Gammacell 40 137Cs 
irradiator (dose rate, 0.82 Gy/min) at Columbia University. 
Six to 48 h after irradiation, cells were stained with PI or 
Annexin-V-FITC + PI and analyzed by flow cytometry for 
cell cycle-apoptosis studies.
FACS Analysis of TRAIL-R2/DR5, FAS and PD-
L1 levels
Surface levels of TRAIL-R2/DR5 (PE anti-human 
DR5 Ab, eBioscience #12-9908), FAS/CD95 (PE anti-
human CD95 mAb, BD Pharmingen #555674), PD-L1 
(CD274) (PE anti-human mAb eBioscience #12-5983) on 
human GBM cell lines were determined by staining with 
the corresponding Abs and subsequent flow cytometry. 
A FACS Calibur flow cytometer (Becton Dickinson, 
Mountain View, CA, USA) and the CellQuest program 
were used to perform flow cytometric analysis. All 
experiments were independently repeated 3-5 times.
Cell viability and cell death studies
The CellTiter-Glo Luminescent Cell Viability Assay 
(“Promega”, Madison, WI53711, USA; #G7570) based on 
quantitation of ATP due to ATP-dependent luminescent 
signal, was performed using the manufactory’s protocol. 
For the induction of apoptosis, cells were exposed to 
CBD (5-40 μM), KU60019 (1-5 μM) and γ-irradiation 
(5-10 Gy) alone or in combination. In some experiments, 
small molecule inhibitors of cell signaling pathways were 
additionally used. Furthermore, apoptosis was induced 
TRAIL and CHX alone or in combination. Apoptosis 
levels (% of apoptotic nuclei) in cells after fixation 
and permeabilization by 70% ethanol were assessed 
by propidium iodide (PI) staining and quantifying 
the percentage of hypodiploid nuclei (pre-G1) using 
FACS analysis. Alternatively, staining of fresh cells by 
Annexin-V-FITC + PI and quantifying the percentage 
of Annexin-V-FITC-positive, PI-negative cells (early 
apoptotic), Annexin-V-FITC-positive, PI-positive cells 
(late apoptotic) and Annexin-V-FITC-negative, PI-positive 
cells (secondary necrotic) was performed using reagents 
from BD Pharmingen (San Diego, CA) that was followed 
by the flow cytometry on FACS Calibur flow cytometer 
(Becton Dickinson) using the CellQuest program or on BD 
FACS Canto System from BD Biosciences. Clonogenic 
survival assay of glioblastoma cells was performed after 
treatment with increased doses of CBD and γ-radiation in 
the presence or absence of an ATM inhibitor KU60019 
(1-2 μM) using a standard method.
Western blot analysis
Total cell lysates (50 μg protein) were resolved 
on SDS-PAGE, and processed according to standard 
protocols. The antibodies used for Western blotting 
included anti-β-Actin mouse mAb (Sigma, St. Louis, MO, 
USA). The antibodies to human antigens obtained from 
Cell Signaling (Danvers, MA) included phospho-p44/
p42 MAPK (Erk1/2) (T202/Y204) rabbit mAb #4377; 
p44/p42 MAPK (Erk1/2) Ab #9102; phospho-SAPK/
JNK (Thr183/Tyr185) rabbit mAb #4668; SAPK/JNK Ab 
#9252; phospho-cJUN (Ser73) Ab#9164; cJUN mouse 
mAb #2315; phospho-p38 MAPK (Thr180/Tyr182) 
rabbit mAb #4511; phospho-ATF2 (Thr71) Ab #9221; 
ATF2 rabbit mAb #9226; phospho-AKT (Ser473) #927; 
AKT Ab #9272; phospho-NF-κB p65 (Ser568) rabbit 
mAb #3033; NF-κB p65 rabbit mAb #4764; phospho-
STAT3 (Tyr705) Ab #9131; STAT3 rabbit mAb #4904; 
phospho-p53 (Ser15) Ab #9284; phospho-p53 (Ser20) Ab 
#9287; p53 Ab #9282; PARP Ab #9542; phospho-ATM 
(Ser1981) mouse mAb #4526; ATM rabbit mAb #2873; 
PD-L1 rabbit mAb #13684. The antibodies obtained from 
Cayman (Ann Arbor, MI) included CB1 receptor Ab 
#101500 and CB2 receptor Ab #101550. The secondary 
antibodies were conjugated to horseradish peroxidase; 
signals were detected using the ECL system (Thermo 
Scientific, Rockford, IL, USA). β-Actin served as a 
loading control.
Quantitative Real-time PCR
U87MG cells were plated in 6-well plates and 
treated with CBD and/or radiation for the indicated 
time. Cells were harvested using Trizol (Thermo Fisher 
Scientific) after washing twice with ice-cold PBS. RNA 
was extracted and converted to cDNA using High Capacity 
cDNA reverse transcription kit (Thermo Fisher Scientific). 
The QPCR primer sequences are listed in Table 1.
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Gene expressions were measured by Life 
Technologies ViiA 7 Real-Time PCR System in standard 
mode. QPCR was analyzed using the comparative CT 
method (ΔΔCT Method). Beta-actin was used as reference 
gene. For each sample, the CT value of the target gene was 
first normalized to the beta-actin CT value to obtain ΔCT. 
Then the ΔCT value was normalized to the control treatment 
(ctrl) within the same time-point to calculate ΔΔCT value. 
Showing in the graph is a 2-ΔΔCT value, which indicates the 
fold change of target gene mRNA levels against time-point 
control after normalization to the reference gene.
Suppression of cell signaling pathways by 
specific inhibitors
We performed inhibition of several signaling 
pathways using JNK1-2 inhibitor SP600125 (20 μM), 
MAPK p38 inhibitor SB203580 (20 μM), IKK-NF-κB 
inhibitor BMS345541 (20 μM); PI3K-AKT inhibitor 
LY294002 (40 μM); and ATM inhibitor KU60019 (1-2 
μM). Western blotting with antibodies to active forms of 
targeted proteins was used to evaluate the effectiveness of 
inhibition. We also assessed changes in apoptosis levels 
under these conditions. All inhibitors were dissolved in 
DMSO as 1000X or 500X stocks; 0.1% or 0.2% DMSO 
was used as a control vehicle.
Statistical analyses of data
Data from four to five independent experiments 
were calculated as means and standard deviations. 
Comparisons of results between treated and control groups 
were made by the Students’ t-tests. A p-value of 0.05 or 
less between groups was considered significant.
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